Venous thrombosis

Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023

The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The urokinase market is being driven by the increasing prevalence of pulmonary embolism (PE), a condition characterized by blood clots in the lungs.
  • Urokinase, a thrombolytic agent, is used to dissolve these clots and is naturally produced by the human body.
  • The urokinase market is highly competitive, featuring numerous players involved in developing and marketing urokinase products.

Paroxysmal Nocturnal Hemoglobinuria Market to Climb Moderately at a CAGR of 7.6% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Monday, January 23, 2023

LAS VEGAS, Jan. 23, 2023 /PRNewswire/ -- DelveInsight's Paroxysmal Nocturnal Hemoglobinuria Market Insights report includes a comprehensive understanding of current treatment practices, paroxysmal nocturnal hemoglobinuria emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • In December 2022, Novartis released the efficacy and adverse event data from the phase III APPLY-PNH trial in paroxysmal nocturnal hemoglobinuria.
  • In September 2022, efficacy and safety data from a phase III trial in paroxysmal nocturnal hemoglobinuria were released by Alexion.
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological disorder characterized by intravascular hemolysis, hemoglobinuria, hemolysis, and venous thrombosis.
  • To know more about paroxysmal nocturnal hemoglobinuria treatment guidelines, visit @ Paroxysmal Nocturnal Hemoglobinuria Management

Florida Cancer Specialists & Research Institute Research Breakthroughs Presented at Global Hematology Gathering

Retrieved on: 
Tuesday, December 13, 2022

Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the diagnosis and treatment of blood diseases was presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition in New Orleans, Louisiana on Dec. 10 – 13, 2022.

Key Points: 
  • Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the diagnosis and treatment of blood diseases was presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition in New Orleans, Louisiana on Dec. 10 – 13, 2022.
  • “The abstracts being presented with FCS participation represent important, novel research and are considered among the best in the field of hematology,” said FCS President & Managing Physician Michael Diaz, MD .
  • Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Retrieved on: 
Thursday, December 8, 2022

Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Key Points: 
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    CABOMETYX in combination with atezolizumab is not indicated as a treatment for NSCLC.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
  • Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.
  • Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

Al Mahmoud Medical Center, Qatar, adopts the geko™ device for prevention of venous thromboembolism (VTE) and reduction of edema (swelling)

Retrieved on: 
Thursday, December 8, 2022

Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.

Key Points: 
  • Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.
  • DOHA, Qatar, Dec. 8, 2022 /PRNewswire/ -- UK-based manufacturer, Firstkind Ltd (a Sky Medical Technology company) and Al Raya Medical Equipment, exclusive distributor for the geko device in Qatar, today announced adoption of the geko device by the Internal Medicine Clinic, at the Al Mahmoud Medical Center in Doha, Qatar.
  • The Al Mahmoud Medical Complex is a Qatari medical clinicthat delivers enhanced care to its patient through our integrated clinical practice.
  • Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each major clinical area.

Al Mahmoud Medical Center, Qatar, adopts the geko™ device for prevention of venous thromboembolism (VTE) and reduction of edema (swelling)

Retrieved on: 
Thursday, December 8, 2022

Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.

Key Points: 
  • Highly eminent, Dr. Mohammad Chikh Atieh, Consultant Internal Medicine at the Al Mahmoud Medical Center, adopts the geko device for the prevention of venous thromboembolism (VTE) and the reduction of edema (swelling) in all aspects of general surgery, obstetrics and gynaecology.
  • DOHA, Qatar, Dec. 8, 2022 /PRNewswire/ -- UK-based manufacturer, Firstkind Ltd (a Sky Medical Technology company) and Al Raya Medical Equipment, exclusive distributor for the geko device in Qatar, today announced adoption of the geko device by the Internal Medicine Clinic, at the Al Mahmoud Medical Center in Doha, Qatar.
  • The Al Mahmoud Medical Complex is a Qatari medical clinicthat delivers enhanced care to its patient through our integrated clinical practice.
  • Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each major clinical area.

ManaMed's Cutting-Edge PlasmaFlow Device Receives UnitedHealthcare Coverage Based Upon Medical Necessity

Retrieved on: 
Thursday, October 13, 2022

DENTON, Texas, Oct. 13, 2022 /PRNewswire/ -- ManaMed strives to be at the forefront of medical innovation, which is why it is excited to announce that its DVT prevention device, PlasmaFlow, has just received UnitedHealthcare coverage.

Key Points: 
  • DENTON, Texas, Oct. 13, 2022 /PRNewswire/ -- ManaMed strives to be at the forefront of medical innovation, which is why it is excited to announce that its DVT prevention device, PlasmaFlow, has just received UnitedHealthcare coverage.
  • PlasmaFlow is a wearable and portable prescription device that helps prevent blood clots during surgery, at discharge, and at home.
  • With PlasmaFlow, ManaMed is confident that it can make a difference in the lives of those who need it most.
  • It has been in the market for over 6 years and nearly one million patients have benefited from this medical device.

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022

Retrieved on: 
Monday, September 19, 2022

REDWOOD CITY, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) today announced the commercial availability, beginning October 3, 2022, of CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all approved indications. CIMERLI is an anti-VEGF therapy within a class of biologics that has been revolutionary in helping retinal patients maintain or gain vision. CIMERLI was approved by the U.S. Food and Drug Administration (FDA) in August 2022, having met FDA’s standards of biosimilarity and interchangeability to the reference product, including safety, efficacy and quality.1

Key Points: 
  • CIMERLI is an anti-VEGF therapy within a class of biologics that has been revolutionary in helping retinal patients maintain or gain vision.
  • As a company, we embrace high performance in everything we do, while valuing our patient-centric approach to our mission.
  • CIMERLI is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in Lucentis and CIMERLI.
  • Coherus licensed CIMERLI from Bioeq AG, a joint venture between Polpharma Biologics Group B.V. and Formycon AG.

Journal of Infusion Nursing Publishes Access Vascular Data Showing Significantly Reduced Complication Rates for HydroMID

Retrieved on: 
Monday, September 19, 2022

In the paper, A Retrospective Assessment of Midline Catheter Failures Focusing on Catheter Composition, complication rates are compared in 101 standard midline catheters and 104 HydroMID catheters.

Key Points: 
  • In the paper, A Retrospective Assessment of Midline Catheter Failures Focusing on Catheter Composition, complication rates are compared in 101 standard midline catheters and 104 HydroMID catheters.
  • The data analysis indicates statistically significant reductions in failure rates, upper extremity deep venous thrombosis, and phlebitis in the HydroMID group, with the polyurethane midline catheters six (6) times more likely to fail then HydroMID catheters.
  • To learn more about Access Vascular and its HydroPICC and HydroMID products, please visit www.accessvascularinc.com .
  • Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis.

Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab

Retrieved on: 
Thursday, August 25, 2022

CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced the initiation of recruitment for its second Phase 3 clinical trial investigating abelacimab, its novel dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa. The MAGNOLIA study is recruiting patients who are at risk of thrombosis and diagnosed with gastrointestinal/genitourinary (GI/GU) cancers, which are cancers known to have a higher risk of bleeding than other cancers1.   The study is one of two complementary, international, multicenter trials where abelacimab is being studied in patients with cancer associated thrombosis (CAT), a condition for which there is an unmet need as currently available anticoagulants have been associated with an increased risk of bleeding2,3. In the MAGNOLIA trial, monthly treatment with abelacimab is being compared with once daily injection of dalteparin, the current anticoagulant standard of care in patients with GI/GU cancers, to assess the effects on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE, a leading cause of death in patients with cancer4.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced the initiation of recruitment for its second Phase 3 clinical trial investigating abelacimab, its novel dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa.
  • Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity.
  • Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
  • Abelacimab targets the active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa.